TS-075141 — THE PROBLEM Current MS treatments typically employ broad immunosuppression rather than targeting specific pathways, resulting in significant side effects and inadequate responses in many patients. The IL-6/STAT3 pathway is critical for balancing inflammatory T effector cells and protective regulato…

TS-038701 — Modality: Small-molecule prodrug that targets the IL-6/STAT3 signaling pathway Stage of Development: Extensive in vitro and in vivo efficacy (3 MS models, incl. relapsing-remitting EAE); preliminary safety Patent Status: Pat. no. 11,420,946 (US); appl. 17/821,286 (US); appl. 18860926.7 (EP); app…